Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28746748 | 0.89 | ALOX15 (0.36) | ALOX15THRBL3MBTL1 | |
| SCHEMBL27935389 | 0.79 | CA1 (0.34) | ALOX15 | |
| SCHEMBL28698674 | 0.78 | — | — | |
| SCHEMBL1878811 | 0.77 | ALDH1A1 (0.43) | ALOX15THRBLMNAALDH1A1KMT2A | |
| SCHEMBL202165 | 0.77 | SLC22A6 (0.39) | ALOX15THRBLMNAALDH1A1 | |
| SCHEMBL2874716 | 0.77 | ALDH1A1 (0.43) | ALOX15THRBLMNAALDH1A1KMT2A | |
| SCHEMBL2844179 | 0.76 | KMT2A (0.41) | ALOX15THRBLMNAMEN1CYP1A2 | |
| SCHEMBL10487113 | 0.76 | ALOX15 (0.33) | ALOX15LMNAMEN1KMT2AHSD17B10 | |
| SCHEMBL21081924 | 0.75 | ALDH1A1 (0.40) | THRBLMNAALDH1A1EPHX1HSD17B10 | |
| SCHEMBL4483900 | 0.75 | TDP1 (0.43) | THRBLMNAALDH1A1EPHX1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539345-B1 | 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| CN-102633680-B | Catalyst for preparing 3,3-diethoxyl propionitrile and preparation method of catalyst | UNIV LANGZHOU | 2014-06-11 | — | — | CN | disclosed |
| CN-102295578-B | Synthetic method of 3,3-diethoxypropionitrile | GANSU RES INST OF CHEMICAL INDUSTRY | 2014-04-02 | — | — | CN | disclosed |
| CN-102295578-A | Synthetic method of 3,3-diethoxypropionitrile | — | 2011-12-28 | — | — | CN | disclosed |
| US-20090192202-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-30 | — | — | US | disclosed |
| US-7507860-B2 | Androgen modulators | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070197641-A1 | Androgen modulators | HU LAIN-YEN | 2007-08-23 | — | — | US | disclosed |
| EP-1737813-A1 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100305-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-4536599-A | HYDROLYZING THE NITRILE DERIVATIVE TO THE AMIDE USING AN ORGANIC QUATERNARY AMINE SALT CATALYST; EFFICIENCY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-08-20 | — | — | US | disclosed |
| EP-0040896-B1 | SYNTHESIS OF AMIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-04-25 | — | — | EP | disclosed |
| EP-0040896-A2 | Synthesis of amides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-12-02 | — | — | EP | disclosed |
| EP-0008532-A1 | Synthesis of amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197641-A1 | Androgen modulators | AR, NR5A1, SHBG | ALOX15 1840/4885THRB 96/4885LMNA 4758/4885 |
| US-20090192202-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | ALOX15 1840/4885THRB 96/4885LMNA 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.